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Objectives: The IBIS-C study, currently ongoing, is the first to assess the burden 
of IBS-C in 6 European countries (France, Germany, Italy, Spain, Sweden, UK) . We 
present an interim analysis of the retrospective data from Spain. MethOds: This is 
an observational, retrospective-prospective (±6-months(m)) study in patients diag-
nosed in the last five years of IBS-C (Rome-III criteria) of moderate-to-severe degree 
(IBS-Symptom Severity Score(IBS-SSS)≥ 175). Quality-of-life(QoL) was assessed 
with the EuroQoL-5D(EQ-5D) and IBS-QoL. Results: We included 46 patients (62% 
severe, mean(±SD) 44.6±12.2 years, 83% women, time since diagnosis 2.8±3.6 years). 
According to IBS-SSS, 94% had abdominal pain in the last month (62% of time) and 
85% abdominal distention. Other prevalent symptoms were: constipation (96%), 
abdominal discomfort (72%) and bloating (59%). Mean IBS-QoL was 46±23, on a scale 
0-100 (worst QoL), and the most affected domains were “food avoidance” (mean:64) 
and “health worry” (60). Mean EQ-5D was 51±20, on a scale 0-100 (best QoL), and 93% 
and 70% of patients, respectively, reported problems in pain/discomfort and anxiety/
depression. In the previous 6m, 83% of patients consulted a primary care physi-
cian, and 89% a specialist (mostly a gastroenterologist)(mean(95%CI):2.8(1.4-4.3) 
and 2.0(0.9-3.1) visits, respectively). 20% of patients required emergency depart-
ment visits or hospitalization (mean stay:1.3(0.6-1.9) days). 76% of patients under-
went a diagnostic test (mean:2.1(1.3-2.9) tests). 89% of patients took medication 
(63% prescription drugs and 54% OTC medications), 26% received complementary 
therapies. The mean direct costs per patient for the National Health System(NHS) 
were € 1,025/6m(549-1627) and the mean costs for the patient were € 200/6m. 17% 
of patients had sick leave(mean:3.5 leaves; mean duration:58 days) and 46% had 
productivity losses(mean:49 hours). Mean indirect costs were € 991/6m. Total costs 
amounted to € 2216/6m. cOnclusiOns: Moderate-to-severe IBS-C has a great 
impact on health care resource utilization and productivity of patients, and the 
results suggest significant costs to the NHS and society. QoL can be severely affected.
PGI45
hEalth-rElatEd QualIty of lIfE (hrQl) In chronIc hEPatItIS c (ch-c)  
PatIEntS trEatEd wIth SofoSBuvIr contaInInG IntErfEron-frEE 
rEGImEnS
Younossi Z.M.1, Stepanova M.1, Nelson D.2, Lawitz E.3, Nader F.1, Hunt S.4
1Inova Fairfax Hospital, Falls Church, VA, USA, 2University of Florida, Gainesvillle, FL, USA, 
3Texas Liver Institute, San Antonio, TX, USA, 4Inova Health System, Falls Church, VA, USA
Objectives: Interferon-containing regimens for treatment of CH-C are associated 
with substantial side effects and significant impairment in HRQL. The aim of this 
study is to evaluate the effect of Interferon-free regimens on HRQL. MethOds: 
Three validated HRQL instruments, namely, Medical Outcomes Study-Short Form 
36 (SF-36), CLDQ-HCV (Chronic Liver Disease Questionnaire-HCV) and FACIT-F 
(Functional Assessment of Chronic Illness Therapy-Fatigue) were administered to 
previously untreated CH-C patients (N= 201) treated with interferon-free regimen 
(Sofosbuvir+Ribavirin) at baseline, during, and after treatment. Patients were ran-
domized to receive 16 weeks of active treatment or 12 weeks of active treatment 
followed by 4 weeks of blinded placebo. Historical data for interferon containing 
regimens were available for all these questionnaires. Results: Small decrements in 
most of the domains of all HRQL metrics were noted at weeks 4, 12, and 16 of active 
treatment regardless of the study arm (maximum observed decrements in HRQL 
summary scores between 3.3% and 8.8% compared to baseline, p< 0.05). There were 
no differences between the study arms at all time points (p> 0.05). These decrements 
were substantially better than historical data available for interferon-containing 
regimens (between 10.4% and 15.2% for the same scores, p< 0.0001). By week 4 of 
follow-up after treatment, some of the social and emotional well-being-related 
domains of FACIT-F improved significantly compared to their own baseline (by 4.9-
6.0%, p< 0.05). At the end of 12-week follow-up, all those domains as well as domains 
of CLDQ-HCV (activity, emotional, worry, systemic domains) further improved (by 
3.8-11.2%, p< 0.05), while physical and functional well-being-related domains of 
FACIT-F and SF-36 returned to their baseline levels or improved moderately (by 3.1-
8.3%, p< 0.05). cOnclusiOns: The impairment in HRQL in CH-C patients treated 
with an interferon-free regimen is minimal and diminishes soon after the end of 
treatment. This interferon-free regimen is associated with substantially better HRQL 
as compared to interferon-containing regimens.
GaStroIntEStInal dISordErS – health care use & Policy Studies
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Objectives: Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The 
objective of this systematic literature review (SLR) was to examine the evidence on 
the efficacy and safety of all available pharmacological interventions for moderate 
to severe UC. MethOds: A systematic literature search using a predefined strategy 
was performed in Medline®, EMBASE®, Medline-In-Process, Cochrane Library and 
BIOSIS from 1966 to 2013, to identify randomized controlled trials (RCTs) concern-
ing the efficacy and safety of available treatments in adult patients with moderate 
to severe UC. Studies reporting on mild-moderate UC patients were included if 
they reported results for the moderate subgroup separately. No language restric-
tions were applied to the search. Results: A total of 4344 abstracts were screened 
based on the predefined selection criteria, of which 4279 were excluded. In total, 
65 publications, reporting results from 65 RCTs were included (49 double blind), 
101 patients completed and returned the second package. Both scales had good 
overall fit to Rasch model (Chi2 p = 0.35; Chi2 p = 0.13 for activity limitations and 
QoL respectively) and unidimensionality of the scales was confirmed. No evidence 
of DIF by age or gender was found and the scales had good coverage of the meas-
urement constructs. Internal consistency was 0.91 for the QoL scale and 0.93 for 
Activity limitations. Good reproducibility was observed (QoL 0.91, Activity limita-
tions 0.89) and both scales were able to distinguish between self-perceived disease 
severity and general health status groups (p< .01). cOnclusiOns: The CLIQ is the 
first CD-specific PRO and is truly patient-based as its content was generated directly 
from CD patients. It is well accepted, completed by patients and is easy to score. 
Both scales measure a clear unidimensional construct and generate valid total 
scores. The scales have good consistency, reproducibility and promising construct 
validity. Studies are planned to assess responsiveness. The CLIQ will prove to be an 
important tool for assessing Activity limitations and QoL in clinical audit, practice 
and trials.
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Objectives: To identify symptoms significantly impacting health-related qual-
ity of life (HRQOL) and how changes in symptoms explain variability in HRQOL 
among adult patients with irritable bowel syndrome with constipation (IBS-
C). MethOds: IBS-C symptom and HRQOL data were pooled from two Phase 3 
trials (n= 1602) assessing efficacy and safety of linaclotide, a guanylate cyclase-C 
agonist approved for adult treatment of IBS-C in the US and moderate to severe 
IBS-C in Europe. IBS-C symptoms measured included abdominal (bloating, cramp-
ing, discomfort, fullness, pain) and bowel (spontaneous bowel movement [SBM] 
and complete SBM [CSBM] frequency, stool consistency, and straining) symptoms. 
HRQOL measures included: a disease-specific Irritable Bowel Syndrome-Quality 
of Life questionnaire (IBS-QOL), and generic HRQOL measures, the EuroQol-5D 
(EQ-5D) and Short Form-12 (SF-12). Analysis of variance evaluated relationships 
between Week 12 change from baseline in IBS-C symptoms and HRQOL, con-
trolling for demographics and baseline HRQOL. Results: Changes in IBS-QOL 
overall score were most significantly impacted by changes in abdominal fullness, 
cramping, and straining (beta coefficients: -1.1, -1.3, -1.7, respectively). The full 
model explained nearly half of the changes in IBS-QOL (R-Square: 0.42). Changes 
in EQ-5D were primarily driven by changes in abdominal bloating, cramping, and 
straining (beta coefficients: -0.009, -0.009, -0.011, respectively, R-Square: 0.49). 
Changes in SF-12 physical and mental component summaries (PCS and MCS) 
were best explained by changes in bloating, cramping, and straining (beta coef-
ficients: -0.41, -0.34, -0.53, respectively; R-square: 0.42), and abdominal fullness 
and CSBM frequency (beta coefficients: -0.59 and 0.26, respectively; R-square: 
0.35), respectively. cOnclusiOns: Improvements in abdominal cramping and 
straining at Week 12 compared to baseline were associated with improvements 
in HRQOL as measured by the IBS-QOL, EQ-5D and SF-12 PCS. Improvements in 
abdominal bloating and fullness, and increases in CSBMs were also associated 
with HRQOL improvements. Targeting improvement in specific IBS-C symptoms 
may result in increased patient HRQOL.
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Objectives: Liver diseases (LDs) have a high impact on morbidity, mortality and 
health-related quality of life (HRQoL). LDs may have different impact on patients’ 
HRQoL. The aim of our study was to evaluate HRQoL in the major liver conditions: 
hepatitis B(HBV), hepatitis C(HCV), cirrhosis(compensated and decompensated), 
hepatocellular carcinoma(HCC), autoimmune hepatitis(AIH), primary biliary 
cirrhosis(PBC), primary sclerosing cholangitis(PSC), NAFLD/NASH, patients in the 
liver transplant list and post-transplant. MethOds: A naturalistic, prospective, 
multicenter study has been conducted to generate and validate a set of health care 
outcomes indicators for the major liver conditions. LDs patients (age> 18 years) were 
enrolled in 3 major Italian medical centers and are still being followed up (median 
f-up:13 months). Within this study, socio-demographic, clinical and HRQoL were 
collected using the EQ-5D-3L. The HRQoL data was analyzed dividing the patients 
in sub-groups according to the most recently diagnosed and most severe condi-
tion. Results: We enrolled 3,217 patients, 64.8% male, aged 19-91 (median= 61) 
years; 95.0% of them filled in the EQ-5D at baseline visit. Patients in the HCC group 
were 22.6%; while in the AIH group were 1.6%. The highest percentage of problems 
in Mobility dimension (39.2%) was reported by decompensated cirrhosis sub-group, 
the highest percentage in Self-care (22.6%) and Usual Activities (47.1%) by patients 
in liver transplant list, in Pain/Discomfort (59.2%) by AIH and in Anxiety/Depression 
(57.8%) by PBC. The HBV sub-group reported the best HRQoL with a mean EQ-5D 
VAS of 77.8; while AIH and listed for liver transplant patients reported the worst 
HRQoL levels (mean EQ-5D VAS= 67.7 and 63.5, respectively). cOnclusiOns: our 
study shows how HRQoL is different between LDs and how it is negatively related 
with the clinical severity. Understanding the different impact of LDs on the patients’ 
HRQoL could help physicians and decision makers to better estimate the burden of 
these conditions and to improve the quality of care.
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and adalimumab (Subcutaneous). The objective of this study was to compare the 
dispensation channel of anti-TNFs used in IBD across European (EU) top 5 coun-
tries. MethOds: We analyzed dispensation conditions using IMS data from 2011 
and official local official websites, France (Haute Autorité de Santé and Health insur-
ance drugs database), Italy (Agenzia Italiana del Farmaco), Spain (Ministerio de 
Sanidad Servicios Sociales e Igualdad), Germany (Gemeinsamer Bundesausschuss), 
United Kingdom (Department of Health). Results: In UK, Spain, Italy, both inflixi-
mab and adalimumab dispensation were restricted to hospital channel. In Germany, 
both infliximab and adalimumab can either be dispensed through retail and hos-
pital channels. In France, adalimumab was available either in hospital and retail 
channels under exceptional status, and infliximab was dispensed through hospital 
channels only. The differences across countries could not be related to products 
labels as they are all approved under European Medicines Agency (EMA) centralized 
procedure. cOnclusiOns: It is unlikely that the gaps observed are only related to 
differences in health care services organization but rather budget constraint like 
in UK, Italy and Spain. In Germany and France, the two leading EU pharmaceuticals 
markets this is not yet the case. Hospital dispensation channel of biologics and 
biosimilars is a new way to generate savings mainly through tenders.
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Objectives: The cost of paediatric gastroenteritis is poorly documented in Asia. 
This analysis reports findings of a survey on disease burden, cost and productivity 
loss caused by paediatric gastroenteritis in Malaysia and Viet Nam. MethOds: A 
survey was conducted between August 2012 and April 2013 targeting respondents 
in public spaces in Hanoi and Bac Giang, Viet Nam and Klang Valley, Malaysia. The 
surveys were self-administered and collected information on demographics, disease 
burden, cost and productivity loss. Descriptive analysis was conducted to report the 
overall findings using STATA SE 11.2. Results: Survey questionnaires were com-
pleted by 245 and 307 respondents from Malaysia and Viet Nam, respectively. Over 
90% of the respondents were parents of children below 10. Overall, 69% reported 
that their children experienced gastroenteritis requiring physician visits and 28% 
reported episodes requiring hospital admissions. Differences were noted in the 
treatment seeking patterns between the two countries. These differences influenced 
cost and productivity loss to the families of affected children. In Malaysia, a large 
proportion of parents (41.2%) reported hospitalisation cost to be more than USD 350 
whereas in Viet Nam, a majority (74.6%) reported hospitalisation cost less than USD 
34. Among these, 52.9% and 30.5% of Malaysian and Vietnamese parents paid out-of-
pocket for hospital admission, respectively. The majority reported days off work of 2 
to 5 days, however more parents in Viet Nam (23.7%) required greater than 6 days off 
work to care for their affected child compared to Malaysia (3.9%). cOnclusiOns: 
Gastroenteritis has an impact on cost and productivity loss to parents of affected 
children in Malaysia and Viet Nam. However, there were several differences noted 
likely due to differences in GDP, health system and cultural factors.
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Objectives: To assess the impact of inflammatory bowel diseases (IBD) in the 
Italian general population: incidence and time trends from 2003 to 2009, as well 
as population characteristics. MethOds: A retrospective observational study was 
conducted in Lombardy, an Italian region with about 10 million of inhabitants, using 
health care administrative databases of the national health care system (HS) which 
provides universal coverage. The main administrative databases were integrated in 
a data warehouse called DENALI using probabilistic record linkage. New cases of 
Crohn’s Disease (CD) and Ulcerative Colitis (UC) were identified in the adult popu-
lation between January 1, 2003 and December 31, 2009. Annual age-standardized 
incidence rates were computed separately for CD and UC using the population 
living in Lombardy at 2001 census. Moreover we evaluated patients’ baseline main 
characteristics, coexisting chronic conditions and survival at December 31, 2009.  
Results: The annual incidence rate per 100,000 person-years of IBD was 15.6 (95%CI 
15.2-15.9); UC and CD incidences were 9.7 (9.4-10.0) and 5.9 (5.7-6.1) respectively. 
Incidence rates of both diseases were higher in men than in women. CD incidence 
was highest in subjects aged 20-24 (9.2, 95%CI 8.1-10.2) and decreased with age, 
while UC incidence was stable in the 20-65 year-old population. No time trends in 
UC and CD incidences were observed from 2003 to 2009, both in the whole study 
population and in gender and age-specific subgroups. The mean age at CD diag-
nosis was 44 years (±16.6 sd), which was lower than that at UC diagnosis (46 ± 16.6, 
p< 0.0001). During a mean follow-up time of 3.4 years (± 2.0) 2.2% of IBD patients 
died. cOnclusiOns: Our study provides updated estimates on current epidemiol-
ogy of IBD in Italy. IBD incidence in Lombardy is lower than in northern Europe and 
the data confirm that UC incidence is higher than that of CD.
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examining aminosalicylates (n= 23), corticosteroids (n= 10), immunosuppressants 
(n= 15), biologics (n= 16) and kinase inhibitors (n= 1). Baseline patient characteristics, 
study design and outcomes were extracted, including: adverse events (AE) (reported 
in n= 24 studies), serious AE (n= 25), deaths (n= 23), clinical remission (n= 49), clini-
cal response (n= 33) and mucosal healing (n= 11). Eleven different disease activity 
scales and four different endoscopic scales were used. The mean age of included 
patients ranged from 27 to 51, and the percentage of males from 28.6% to 87.5%. Due 
to large differences and different scales used for reporting efficacy it is not feasible 
to report the range across different scales. Safety endpoints were also reported 
inconsistently. The results per outcome are presented in a narrative way per treat-
ment class. cOnclusiOns: A comprehensive SLR performed which identified 65 
RCT reporting on the efficacy and safety of pharmacological treatments in moderate 
to severe UC patients. Differences in patient population, disease severity, disease 
activity scales and trial duration are explored and presented.
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Objectives: To assess the impact of new HCV drugs pricing strategy on the number 
of potential treated/cured patients and on the Italian Healthcare Service budget, 
using a simplistic model to design different scenarios for second generation direct 
antiviral agents (DAAs). MethOds: We calculated the HCV drugs budget and the 
number of patients for setting a base case by summing a) AIFA values for HCV 
dual therapy drugs to assess the number of patients currently treated; b) triple 
therapy number of patients estimated from AIFA budget (210.000.000€ in total). 
We performed budget scenarios on two variables: 1) pricing strategy of more effec-
tive DAAs; 2) total HCV drugs budget. We calculated the number of treated and 
responder patients, considering only genotype 1 HCV to maintain a comparability 
between base case and future scenarios with new DAAs. Results: The number of 
patients to be cured with stable budget vs base case are: 1) 9.000 (+56% vs. base case) 
with parity price vs. triple therapy; 2) 7.500 (+30% vs. base case) in case of a 20% 
premium price that would allow 8.300 patients to be treated. Assuming to double 
the allocated budget from payers (420.000.000€ ) and to reduce the new DAAs price 
by a 20%, 25.000 patients will be treated and 22.500 (+291% vs. base case) will be 
cured. cOnclusiOns: This simplified analysis shows that more effective drugs can 
significantly increase the number of patients who could be treated and cured. In 
order to support these results, efforts from both payers (higher budget) and pharma 
companies (lower prices) are needed.
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Objectives: The objective of this study is to examine health care expenditures asso-
ciated with Gastro-esophageal Reflux Disease (GERD) among elderly with Chronic 
Obstructive Pulmonary Disease (COPD) and understand the explanatory factors 
associated with incremental expenditures associated with (GERD). MethOds: The 
study utilized retrospective cross-sectional design. Data were extracted from multiple 
years (2006-2009) of the Medicare Current Beneficiaries Survey (MCBS). The analytical 
sample consisted of community dwelling elderly individuals with COPD (n = 3,821) 
identified using appropriate International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) codes. The key independent variable was defined 
as presence or absence of GERD. T-tests and ordinary least squares regressions (OLS) 
on log-transformed total health care expenditures were performed to analyze the 
association between health care expenditures with GERD among individuals with 
COPD. Blinder-Oaxaca decomposition analysis was performed to estimate contribu-
tion of factors towards explaining the excess health care expenditures. Results: 
Among elderly individuals with COPD, the annual average health care expenditures 
were higher for those with GERD ($36,793 ± $1,387) as compared to those without 
GERD ($24,722 ± $800). Individuals with GERD had poorer health status, low physi-
cal activity profile, and higher rates of obesity. Furthermore, the rates of depression 
and anxiety were significantly higher among individuals with GERD compared to 
those without GERD. A decomposition technique revealed that nearly 30.9% of the 
incremental health care spending associated with GERD was due to the differences in 
characteristics such as Charlson’s comorbitity score (17.5%), perceived health status 
(7.13%) and depression (5.85%). cOnclusiOns: Our findings highlight the burden 
of comorbid conditions among those with COPD and GERD. This study reinforces the 
need to modify the care-delivery model from single-disease care approach to inte-
grated/ multiple diseases care approach to manage the complex comorbid diseases, 
which may ultimately reduce the excess health care expenditures.
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Objectives: In The Netherlands, the funding for some high cost drugs and particu-
larly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A 
European study forecast (2012-2016) shown hospital dispensation as a very effective 
policy to reduce budget impact of branded biologics and increase savings related 
to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel 
Disease (IBD) in EU with different mode of administration: infliximab (Intravenous) 
